CureVac NV logo

CVAC - CureVac NV Share Price

$102.69 1.6  1.6%

Last Trade - 22/01/21

Sector
Healthcare
Size
Large Cap
Market Cap £13.36bn
Enterprise Value £12.59bn
Revenue £20.0m
Position in Universe 588th / 6630
Bullish
Bearish
Unlock CVAC Revenue
Momentum
Relative Strength (%)
1m -2.42%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 12.9 17.4 59.4 945.1 +35.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2020, CureVacBV revenues totaled EUR8.3M. Net loss totaled to EUR60.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CVAC Revenue Unlock CVAC Revenue

Net Income

CVAC Net Income Unlock CVAC Revenue

Normalised EPS

CVAC Normalised EPS Unlock CVAC Revenue

PE Ratio Range

CVAC PE Ratio Range Unlock CVAC Revenue

Dividend Yield Range

CVAC Dividend Yield Range Unlock CVAC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CVAC EPS Forecasts Unlock CVAC Revenue
Profile Summary

CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 177,968,203
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CVAC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CVAC
Upcoming Events for CVAC
Frequently Asked Questions for CureVac NV
What is the CureVac NV share price?

As of 22/01/21, shares in CureVac NV are trading at $102.69, giving the company a market capitalisation of £13.36bn. This share price information is delayed by 15 minutes.

How has the CureVac NV share price performed this year?

Shares in CureVac NV are currently trading at $102.69 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CureVac NV price has moved by % over the past year.

What are the analyst and broker recommendations for CureVac NV?

There are no analysts currently covering CureVac NV.

When will CureVac NV next release its financial results?

CureVac NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the CureVac NV dividend yield?

CureVac NV does not currently pay a dividend.

Does CureVac NV pay a dividend?

CureVac NV does not currently pay a dividend.

When does CureVac NV next pay dividends?

CureVac NV does not currently pay a dividend.

How do I buy CureVac NV shares?

To buy shares in CureVac NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CureVac NV?

Shares in CureVac NV are currently trading at $102.69, giving the company a market capitalisation of £13.36bn.

Where are CureVac NV shares listed? Where are CureVac NV shares listed?

Here are the trading details for CureVac NV:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CVAC
What kind of share is CureVac NV?

Based on an overall assessment of its quality, value and momentum, CureVac NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CureVac NV share price forecast 2021?

Shares in CureVac NV are currently priced at $102.69. At that level they are trading at 41.27% premium to the analyst consensus target price of 0.00.

Analysts covering CureVac NV currently have a consensus Earnings Per Share (EPS) forecast of -2.3440363278 for the next financial year.

How can I tell whether the CureVac NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CureVac NV. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $102.69, shares in CureVac NV are trading at 40.39% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CureVac NV PE Ratio?

We were not able to find PE ratio data for CureVac NV.

Who are the key directors of CureVac NV?

We were unable to find the directors for CureVac NV.

Who are the major shareholders of CureVac NV?

Here are the top five shareholders of CureVac NV based on the size of their shareholding:

DH Capital GmbH & Co. KG Corporation
Percentage owned: 49.18% (87.5m shares)
KfW Bank and Trust
Percentage owned: 16.78% (29.9m shares)
Glaxo Group, Ltd. Holding Company
Percentage owned: 8.39% (14.9m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 2.19% (3.90m shares)
Scottish Mortgage Investment Trust PLC Mutual Fund
Percentage owned: 1% (1.77m shares)
Similar to CVAC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.